CLS.CN reported on April 12 that Andon Health announced that the net profit in the first quarter is expected to be CNY 14 billion to CNY 16 billion, a year-on-year increase of 36707.43% to 41965.63%.

Behind Andon Health's dazzling performance forecast, "antigen" has become a key word.

During the reporting period, the company's iHealth US subsidiary sold iHealth's COVID-19 antigen detection kit products through its own channels and the Amazon platform, and signed major contracts and orders with customers. The increase in sales revenue of this product made an important contribution to the company's performance during the reporting period. The company also disclosed the 2021 performance report: the operating income in 2021 will be CNY 2.513 billion, a year-on-year increase of 25.11%; the net profit attributable to the parent is CNY 913 million, a year-on-year increase of 276.87%; basic earnings per share are CNY 2.01.